Scope International AG is an internationally active Contract Research Organization (CRO) based in Mannheim, providing services to the pharmaceutical industry. The company specializes in the planning, organization, and execution of clinical trials regarding the efficacy and safety of medicinal products. Additionally, Scope offers proprietary software solutions such as the Clinical Trial Management System InSIGHT and the safety reporting system SCORIS. Furthermore, the company supports clients through its subsidiary PURPLE & PINE GmbH with communication and patient recruitment for clinical trials.
Dienstleistungen für die internationale pharmazeutische Industrie sowie alle damit verbundenen Geschäfte und Dienstleistungen, ausgenommen erlaubnispflichtige.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 9421 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Gerald Meub | Vorstand | Darmstadt |
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 9421 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 07.10.2025 | Registered Seat Change | SCOPE INTERNATIONAL AG, 20124 |
| 07.10.2025 | Business Address Change | VIA GIUSEPPINA LAZZARONI 8, 20124 Milano/Italien |
| 05.09.2016 | Satzung amended | Satzung |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 12.10.2005 | Share Capital Set | — | 502.192 € |
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 9421 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€10.6M2 | -€198,663 | €13,320,456 | 97 |
| 2023 | Rohergebnis€12.9M2 | €464,679 | €13,975,972 | 104 |
| 2022 | Rohergebnis€13.1M2 | €479,467 | €13,796,949 | 107 |
| 2021 | Rohergebnis€14M2 | €285,435 | €13,767,626 | 104 |
| 2020 | Rohergebnis€12.4M2 | €296,042 | €11,932,745 | 104 |
| 2019 | Rohergebnis€12.8M2 | €413,538 | €11,337,170 | 112 |
| 2018 | Rohergebnis€13.5M2 | €406,934 | €11,447,340 | 114 |
| 2017 | Rohergebnis€13.5M2 | €293,151 | €11,983,030 | 111 |
| 2016 | Rohergebnis€13.5M2 | €243,581 | €9,161,727 | 107 |
| 2015 | Rohergebnis€13.5M2 | €583,347 | €13,069,979 | 106 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 9421 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,655,344 | 96.0% |
| Depreciation | €226,222 | 3.8% |
| Interest & Similar | €12,154 | 0.2% |
